Hospital admission due to warfarin potentiation by TMP-SMX.
Chafin
C C
CC
University of Tennessee, Memphis, USA.
Ritter
B A
BA
James
A
A
Self
T H
TH
D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D002545:Brain Ischemia / Q000517:prevention & control; D004347:Drug Interactions; D004357:Drug Synergism; D006760:Hospitalization; D006801:Humans; D008297:Male; D009730:Nursing Assessment; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*; D014552:Urinary Tract Infections / Q000517:prevention & control; D014859:Warfarin / Q000009:adverse effects*
D000892:Anti-Infective Agents, Urinary; D000925:Anticoagulants; D014859:Warfarin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination